Difference between revisions of "RHEUMATOID ARTHRITIS-MANAGEMENT (OTHER NON BIOLOGIC DMARDs)"
(Imported from text file) |
(Imported from text file) |
||
| (One intermediate revision by the same user not shown) | |||
| Line 1: | Line 1: | ||
===== [[Summary Article|'''SUMMARY''']] ===== | ===== [[Summary Article|'''SUMMARY''']] ===== | ||
1. Leflunomide: pyrimidine antagonist and may be used as an initial DMARD in patients unable to take MTX. SE: diarrhea, respiratory infections, hepatotoxicity, teratogenicity. | 1. Leflunomide: pyrimidine antagonist and may be used as an initial DMARD in patients unable to take MTX. SE: diarrhea, respiratory infections, hepatotoxicity, teratogenicity. | ||
<br/> | |||
<br/>2. Hydroxychloroquine. SE: retinopathy, patients require baseline optometry prior to commencing the drug. | <br/>2. Hydroxychloroquine. SE: retinopathy, patients require baseline optometry prior to commencing the drug. | ||
<br/> | |||
<br/>3. Sulfasalazine. SE: sulfa-allergic reactions, myelosuppression, GI disturbance. | <br/>3. Sulfasalazine. SE: sulfa-allergic reactions, myelosuppression, GI disturbance. | ||
==Reference(s)== | ==Reference(s)== | ||
Wilkinson, I. (2017). Oxford handbook of clinical medicine. Oxford: Oxford University Press. | Wilkinson, I., Furmedge, D. and Sinharay, R. (2017). Oxford handbook of clinical medicine. Oxford: Oxford University Press. [https://amzn.to/3YHrI6K Get it on Amazon.] | ||
<br/>Feather, A., Randall, D. and Waterhouse, M. (2020). Kumar And Clark’s Clinical Medicine. 10th ed. S.L.: Elsevier Health Sciences. [https://amzn.to/3k7WSW0 Get it on Amazon.] | |||
<br/>Hannaman, R. A., Bullock, L., Hatchell, C. A., & Yoffe, M. (2016). Internal medicine review core curriculum, 2017-2018. CO Springs, CO: MedStudy. | <br/>Hannaman, R. A., Bullock, L., Hatchell, C. A., & Yoffe, M. (2016). Internal medicine review core curriculum, 2017-2018. CO Springs, CO: MedStudy. | ||
<br/>Therapeutic Guidelines. Melbourne: Therapeutic Guidelines Limited. https://www.tg.org.au [Accessed 2021]. | <br/>Therapeutic Guidelines. Melbourne: Therapeutic Guidelines Limited. https://www.tg.org.au [Accessed 2021]. | ||
Latest revision as of 11:07, 20 March 2023
SUMMARY
1. Leflunomide: pyrimidine antagonist and may be used as an initial DMARD in patients unable to take MTX. SE: diarrhea, respiratory infections, hepatotoxicity, teratogenicity.
2. Hydroxychloroquine. SE: retinopathy, patients require baseline optometry prior to commencing the drug.
3. Sulfasalazine. SE: sulfa-allergic reactions, myelosuppression, GI disturbance.
Reference(s)
Wilkinson, I., Furmedge, D. and Sinharay, R. (2017). Oxford handbook of clinical medicine. Oxford: Oxford University Press. Get it on Amazon.
Feather, A., Randall, D. and Waterhouse, M. (2020). Kumar And Clark’s Clinical Medicine. 10th ed. S.L.: Elsevier Health Sciences. Get it on Amazon.
Hannaman, R. A., Bullock, L., Hatchell, C. A., & Yoffe, M. (2016). Internal medicine review core curriculum, 2017-2018. CO Springs, CO: MedStudy.
Therapeutic Guidelines. Melbourne: Therapeutic Guidelines Limited. https://www.tg.org.au [Accessed 2021].
